Author

R. A. DePinho

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:cancer & tumor microenvironment· 5 Organism:mouse· 4 Research Focus:cell type annotation· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

F. L. Muller· 3 shared J. M. Asara· 2 shared S. Khadka· 2 shared Y. Chen· 2 shared Y.-H. Lin· 2 shared A. C. Liu· 1 shared A. Carracedo· 1 shared A. Chatoff· 1 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. L. Muller

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Mediator Subunit Med4 Enforces Metastatic Dormancy in Breast Cancer

S.-Y. Bae, H.-H. Ling, Y. Chen, H. Chen, D. Kumar, J. Zhang, A. D. Viny, R. A. DePinho, F. G. Giancotti

This study identifies Med4 as a regulator of metastatic dormancy in breast cancer, showing its role in maintaining chromatin structure and suppressing enhancer activation.

bioRxiv · Nov 18, 2023Cancer Biology

KRAS inhibition activates an actionable CD24 do-not-eat-me signal in pancreatic cancer

Y. Wei, M. Liu, E.-Y. Yen, J. Yao, Z. Xun, P. T. Nguyen, X. Wang, Z. Yang, A. Yousef, D. Pan, Y. Jin, C.-F. Li, M. S. Theardy, J. Park, Y. Cai, , H. Ying

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.

bioRxiv · Sep 21, 2023Cancer Biology

Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism

S. Khadka, Y.-H. Lin, J. J. Ackroyd, Y.-A. Chen, Y. Sheng, W. Qian, S. Guo, Y. Chen, E. I. Behr, Y. Barekatain, M. N. Uddin, K. Arthur, V. C. Yan, E. Chang, A. Poral, , F. L. Muller

This study shows that angiogenesis inhibitors enhance the effectiveness of metabolic therapies in gliomas by inducing anaplerotic nutrient stress.

bioRxiv · May 7, 2023 · PreprintCancer Biology

NAD+ biosynthesis as a collateral lethality target for precision oncology

F. L. Muller, P. Deng, N. Satani, Y.-H. Lin, N. Hammoudi, G. Mohapatra, J. M. Asara, R. A. DePinho

The paper identifies NMNAT2 as a collateral lethality target in cancers with NMNAT1 deletions, showing selective toxicity in vitro and tumor eradication in vivo.

bioRxiv · Dec 13, 2022 · PreprintCancer Biology

Genetic depletion of de novo coenzyme A biosynthesis exacerbates puromycin toxicity

S. Khadka, A. Chatoff, N. W. Snyder, R. A. DePinho, F. L. Muller

The paper shows that reducing coenzyme A biosynthesis increases cancer cells' sensitivity to puromycin, a selection antibiotic used in research.

bioRxiv · Sep 6, 2022 · PreprintCancer Biology

Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma

S. M. Davidson, J. E. Heyman, J. P. O'Brien, A. C. Liu, D. R. Schmidt, W. J. Israelsen, T. L. Dayton, R. Sehgal, R. Bronson, E. Freinkman, H. Mak, S. Malstrom, G. Bellinger, A. Carracedo, P. P. Pandolfi, , M. G. Vander Heiden

The paper investigates the role of pyruvate kinase isoforms in prostate cancer, finding that Pkm1 suppresses cancer while Pkm2 promotes it, and that a PKM1-like activator can suppress tumor progression.

bioRxiv · May 9, 2021Cancer Biology